bluuebunny/crossref_metadata_2025_split huggingface dataset:
Systematic review with meta-analysis: effectiveness of hyperbaric oxygenation therapy for ulcerative colitis
Authors: Chen Pingrun , Li Yina , Zhang Xian , Zhang Yan 
Published: July 2021

Background and aims: Hyperbaric oxygenation therapy has been used in the treatment of ulcerative colitis in the past few years. However, its efficacy still remains unclear. The aim of the study was to investigate the efficacy of hyperbaric oxygen combination therapy in patients with ulcerative colitis. Methods: We conducted a comprehensive study search up to September 2020, from the online databases Embase, PubMed, Cochrane Library, China National Knowledge Infrastructure, WanFang and VIP. Results: Thirteen studies comprising 780 patients were included. We found that compared with conventional therapy, hyperbaric oxygen combination therapy was superior in reaching clinical remission [risk ratio (RR)=1.62; 95% confidence interval (CI) 1.42 to 1.84; p < 0.001] and clinical response (RR=1.29; 95% CI 1.21 to 1.38; p < 0.001), with lower disease activity scores [standard mean difference (SMD)= −1.19; 95%CI −1.74 to −0.65; p < 0.001]. An obvious reduction of serum levels of tumor necrosis factor-α (SMD= −1.96; 95%CI −2.50 to −1.41; p < 0.001) and interleukin (IL)-6 (SMD= −2.49; 95% CI −2.84 to −2.15; p < 0.001), and elevation of IL-10 level (SMD=2.40; 95% CI 0.68 to 4.12; p = 0.006) were also observed. Conclusion: Hyperbaric oxygen combination therapy was effective in patients with ulcerative colitis, and has potential as a complementary method for its treatment.
Investigation of the structure and compressive strength of a bioceramic root canal sealer reinforced with nanomaterials
Authors: Baghdadi Inaam , AbuTarboush Belal J , Zaazou Ashraf , Skienhe Hasan , Özcan Mutlu , Zakhour Mirvat , Salameh Ziad 
Published: July 2021

Objectives: A root canal sealer that can increase the resistance of endodontically treated teeth to compressive strength would be of great advantage. The purpose of this study is to use three different nanoparticles: multi-walled carbon nanotubes (MWCNTs), Titanium carbides (TC), and Boron nitrides (BN) into a bioceramic adhesive root canal sealer; BioRoot™ RCS, in an attempt to improve its structural and compressive strength properties. Methods: Three composites of two weight fractions (1- and 2-wt.%) were produced by mixing each nanomaterial separately with a pre-weighed mass of Bioroot powder. The microstructural properties and compressive strength of the different hardened composites obtained were investigated. The composites have been characterized by X-ray Diffraction, Fourier transform infrared spectroscopy, and scanning electron microscopy. Compression testing was performed. Results: The 1-wt.% composites, Bioroot/MWCNTs, and Bioroot/TC, except for the one reinforced with BN, displayed a significant improvement in the compressive strength compared to pristine BioRoot™ RCS. The 2-wt.% composites showed no significant improvement in the compressive strength. Conclusion: The addition of 1-wt.% MWCNTs and TC nanomaterials can be considered in the future for enhancing the microstructure and compressive strength properties of pristine BioRoot™ RCS.
Periodontal Disease and Oral Health–Related Quality of Life in the Older Population in Indonesia
Authors: Hijryana M. , MacDougall M. , Ariani N. , Saksono P. , Kusdhany L.S. , Walls A.W.G. 
Published: July 2021

Introduction: Despite being acknowledged as the second global burden of oral disease, periodontal disease has few epidemiologic studies in the literature, particularly for developing countries. Many previous studies have assessed the relationship between periodontal disease and oral health–related quality of life (OHRQoL), with patients attending dental clinic or hospitals rather than a general population. This study attempted to fill the knowledge gap in limited information about periodontal disease and OHRQoL, with reference to a general population in a developing country. Objectives: To investigate the relationship between OHRQoL and periodontal diseases in an older population in Indonesia. Methods: We invited 582 older people from community health centers. The 369 (63.4%) older people who agreed to participate consented to an oral health examination and a questionnaire capturing demographic, socioeconomic, behavioral, and Oral Health Impact Profile–14 (OHIP-14) data. Results: Almost 75% of the older people had generalized periodontitis; 3% had healthy periodontal status; and around 22% had localized periodontitis. There was a lack of statistical evidence for an association between periodontal disease status and OHRQoL. This result was based on the appraisal of the prevalence of the impact (Odds ratio [OR], 0.95 [95% CI, 0.54 to 1.59]; P = 0.77), difference in mean severities (0.07 [95% CI, –1.66 to 1.80]; P = 0.94), and extent of the impact (P = 0.996). However, we found evidence for a relationship between tooth mobility and OHRQoL for all of the OHIP assessments, including prevalence of the impact (OR, 1.87 [95% CI, 1.16 to 3.01]; P = 0.009), difference in mean severities (–2.98 [95% CI, –4.50 to –1.45]; P < 0.001), and extent of the impact (P = 0.001). Conclusion: There was a lack of statistical evidence for a relationship between periodontal disease status and OHRQoL in this society. However, we found evidence that tooth mobility, as a sign of periodontal disease progression, is related to OHRQoL. Knowledge Transfer Statement: The present study can be used by dentists, community health workers, and policy makers in Indonesia to understand the prevalence, severity, and extent of the negative impacts of periodontal disease on older people’s quality of life. In addition, this study provides information about factors that might considerably affect the oral health–related quality of life in this society, such as brushing habits, dental visit, family income, DMF-T status, and subjective appraisal toward dental health.
Alzheimer’s and Consciousness: How Much Subjectivity Is Objective?
Authors: Bajic Vladan , Misic Natasa , Stankovic Ivana , Zaric Bozidarka , Perry George 
Published: July 2021

Does Alzheimer Disease show a decline in cognitive functions that relate to the awareness of external reality? In this paper, we will propose a perspective that patients with increasing symptoms of AD show a change in the awareness of subjective versus objective representative axis of reality thus consequently move to a more internal like perception of reality. This paradigm shift suggests that new insights into the dynamicity of the conscious representation of reality in the AD brain may give us new clues to the very early signs of memory and self-awareness impairment that originates from, in our view the microtubules. Dialog between Adso and William, in Umberto Eco’s The Name of the Rose, Third Day: Vespers. “But how does it happen,” I said with admiration, “that you were able to solve the mystery of the library looking at it from the outside, and you were unable to solve it when you were inside?” “Thus, God knows the world, because He conceived it in His mind, as if it was from the outside, before it was created, and we do not know its rule, because we live inside it, having found it already made.”
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
Authors: Belvís Robert , Irimia Pablo , Pozo-Rosich Patricia , González-Oria Carmen , Cano Antonio , Viguera Javier , Sánchez Belén , Molina Francisco , Beltrán Isabel , Oterino Agustín , Cuadrado Elisa , Gómez-Camello Angel , Alberte-Woodward Miguel , Jurado Carmen , Oms Teresa , Ezpeleta David , de Terán Javier Díaz , Morollón Noemí , Latorre Germán , Torres-Ferrús Marta , Alpuente Alicia , Lamas Raquel , Toledano Carlos , Leira Rogelio , Santos Sonia , del Río Margarita Sánchez 
Published: July 2021

AbstractBackgroundErenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. The Spanish Neurological Society started a prospective registry to evaluate real-world effectiveness and tolerability, and all Spanish headache experts were invited to participate. We present their first results.MethodsPatients fulfilled the ICHD-3 criteria for migraine and had ≥ 4 MMDs. Sociodemographic and clinical data were registered as well as MMDs, monthly headache days, MHDs, prior and concomitant preventive treatment, medication overuse headache (MOH), migraine evolution, adverse events, and patient-reported outcomes (PROs): headache impact test (HIT-6), migraine disability assessment questionnaire (MIDAS), and patient global improvement change (PGIC). A > 50% reduction of MMDs after 12 weeks was considered as a response.ResultsWe included 210 patients (female 86.7%, mean age 46.4 years old) from 22 Spanish hospitals from February 2019 to June 2020. Most patients (89.5%) suffered from chronic migraine with a mean evolution of 8.6 years. MOH was present in 70% of patients, and 17.1% had migraine with aura. Patients had failed a mean of 7.8 preventive treatments at baseline (botulinum toxin type A—BoNT/A—had been used by 95.2% of patients). Most patients (67.6%) started with erenumab 70 mg. Sixty-one percent of patients were also simultaneously taking oral preventive drugs and 27.6% were getting simultaneous BoNT/A. Responder rate was 37.1% and the mean reduction of MMDs and MHDs was -6.28 and -8.6, respectively. Changes in PROs were: MIDAS: -35 points, HIT-6: -11.6 points, PIGC: 4.7 points. Predictors of good response were prior HIT-6 score < 80 points (p = 0.01), ≤ 5 prior preventive treatment failures (p = 0.026), absence of MOH (p = 0.039), and simultaneous BoNT/A treatment (p < 0.001). Twenty percent of patients had an adverse event, but only two of them were severe (0.9%), which led to treatment discontinuation. Mild constipation was the most frequent adverse event (8.1%).ConclusionsIn real-life, in a personalized managed access program, erenumab shows a good effectiveness profile and an excellent tolerability in migraine prevention in our cohort of refractory patients.
HAVoC, a bioinformatic pipeline for reference-based consensus assembly and lineage assignment for SARS-CoV-2 sequences
Authors: Truong Nguyen Phuoc Thien , Plyusnin Ilya , Sironen Tarja , Vapalahti Olli , Kant Ravi , Smura Teemu 
Published: July 2021

Abstract
Background
SARS-CoV-2 related research has increased in importance worldwide since December 2019. Several new variants of SARS-CoV-2 have emerged globally, of which the most notable and concerning currently are the UK variant B.1.1.7, the South African variant B1.351 and the Brazilian variant P.1. Detecting and monitoring novel variants is essential in SARS-CoV-2 surveillance. While there are several tools for assembling virus genomes and performing lineage analyses to investigate SARS-CoV-2, each is limited to performing singular or a few functions separately.

Results
Due to the lack of publicly available pipelines, which could perform fast reference-based assemblies on raw SARS-CoV-2 sequences in addition to identifying lineages to detect variants of concern, we have developed an open source bioinformatic pipeline called HAVoC (Helsinki university Analyzer for Variants of Concern). HAVoC can reference assemble raw sequence reads and assign the corresponding lineages to SARS-CoV-2 sequences.

Conclusions
HAVoC is a pipeline utilizing several bioinformatic tools to perform multiple necessary analyses for investigating genetic variance among SARS-CoV-2 samples. The pipeline is particularly useful for those who need a more accessible and fast tool to detect and monitor the spread of SARS-CoV-2 variants of concern during local outbreaks. HAVoC is currently being used in Finland for monitoring the spread of SARS-CoV-2 variants. HAVoC user manual and source code are available at https://www.helsinki.fi/en/projects/havoc and https://bitbucket.org/auto_cov_pipeline/havoc, respectively.
The association between atrial fibrillation and in-hospital outcomes in chronic kidney disease patients with acute coronary syndrome: findings from the improving care for cardiovascular disease in China-acute coronary syndrome (CCC-ACS) project
Authors: Yang Lijiao , Ye Nan , Wang Guoqin , Bian Weijing , Xu Fengbo , Zhao Dong , Liu Jing , Hao Yongchen , Liu Jun , Yang Na , Cheng Hong ,   CCC-ACS
Published: July 2021

Abstract
Background
Atrial fibrillation (AF) is the most common cardiac arrhythmia in patients with chronic kidney disease (CKD) and acute coronary syndrome (ACS). This study aimed to explore the frequency and impact of AF on clinical outcomes in CKD patients with ACS.

Methods
CKD inpatients with ACS between November 2014 and December 2018 were included based on the improving care for cardiovascular disease in China-ACS (CCC-ACS) project. Included patients were divided into an AF group and a non-AF group according to the discharge diagnosis. Multivariable logistic regression was used to adjust for potential confounders.

Results
A total of 16,533 CKD patients with ACS were included. A total of 1418 (8.6%) patients had clinically recognized AF during hospitalization, 654 of whom had an eGFR of 45 to < 60 ml/min/1.73 m2, and 764 had an estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73 m2. Compared with the non-AF group, the AF group had a higher risk of in-hospital mortality [OR 1.250; 95% CI (1.001–1.560), P = 0.049] and major adverse cardiovascular events (MACEs) [OR 1.361; 95% CI (1.197–1.547), P < 0.001]. We also found that compared with patients with eGFR 45 to < 60 ml/min/1.73 m2, patients with eGFR < 45 ml/min/1.73 m2 had a 1.512-fold increased risk of mortality and a 1.435-fold increased risk of MACEs.

Conclusions
AF was a risk factor affecting the short-term prognosis of ACS patients in the CKD population. Furthermore, the lower the eGFR, the higher the risk of in-hospital mortality and MACEs in CKD patients with ACS.
Trial registry: Clinicaltrial.gov, NCT02306616. Registered 29 November 2014, https://clinicaltrials.gov/ct2/show/NCT02306616?term=NCT02306616&draw=2&rank=1
Association between cervical dysplasia and female genital schistosomiasis diagnosed by genital PCR in Zambian women
Authors: Rafferty H. , Sturt A. S. , Phiri C. R. , Webb E. L. , Mudenda M. , Mapani J. , Corstjens P. L. A. M. , van Dam G. J. , Schaap A. , Ayles H. , Hayes R. J. , van Lieshout L. , Hansingo I. , Bustinduy A. L. 
Published: July 2021

Abstract
Background
Female genital schistosomiasis (FGS) is a neglected tropical gynaecological disease that affects millions of women in sub-Saharan Africa (SSA). FGS is caused by Schistosoma haematobium, a parasitic carcinogen involved in the pathogenesis of squamous cell carcinoma of the bladder. Cervical cancer incidence and mortality are highest in SSA, where pre-cancerous cervical dysplasia is often detected on screening with visual inspection with acetic acid (VIA). There are no studies evaluating the association between VIA positivity and FGS diagnosed by genital PCR.

Methods
Women were recruited from the Bilharzia and HIV (BILHIV) study in Zambia a community-based study comparing genital self-sampling to provider obtained cervicovaginal-lavage for the diagnosis of FGS in women aged 18–31. FGS was defined as positive Schistosoma DNA from any genital PCR. Urogenital schistosomiasis diagnostics included urine circulating anodic antigen, urine microscopy and portable colposcopy. Participants were offered cervical cancer screening using VIA at Livingstone Central Hospital. Associations of PCR confirmed FGS and other diagnostics with VIA positivity were assessed using multivariable logistic regression.

Results
VIA results were available from 237 BILHIV participants. A positive Schistosoma PCR in any genital specimen was detected in 14 women (5.9%), 28.6% (4/14) of these women had positive VIA compared to 9.0% without PCR evidence of schistosome infection (20/223). Schistosoma PCR positivity in any genital specimen was strongly associated with VIA positivity (OR: 6.08, 95% CI: 1.58–23.37, P = 0.02).

Conclusions
This is the first study to find an association between FGS and positive VIA, a relationship that may be causal. Further longitudinal studies are needed.
Pregnancy complicated with hepatitis B virus infection and preterm birth: a retrospective cohort study
Authors: Zheng Shuisen , Zhang Huale , Chen Rongxing , Yan Jianying , Han Qing 
Published: July 2021

AbstractBackgroundWe aimed to investigate whether maternal chronic hepatitis B virus (HBV) infection affects preterm birth (PTB) in pregnant women.MethodsWe retrospectively analyzed HBV-infected and non-infected pregnant women attending antenatal care at Fujian Maternity and Child Health Hospital, Fuzhou, China between January 1, 2016 to December 31, 2018. Participants were divided into HBV infection (n = 1302) and control (n = 12,813) groups. We compared baseline data, pregnancy and perinatal complications, and preterm delivery outcomes between groups. Performed multiple logistics regression analysis to adjust for confounding factors. Finally, we compared early PTB outcome between different HBV DNA level groups.ResultsThe incidence of preterm birth (gestation less than 37 weeks) was similar between the groups, early preterm birth (gestation less than 34 weeks) were significantly more among the HBV infection group than among the controls (1.6% VS. 0.8%;P = 0.003). After adjusting for confounding factors through logistics regression, HBV infection was found to be an independent early PTB risk factor gestation (adjusted odds ratio 1.770; 95% confidence interval [1.046–2.997]). The incidence of early PTB in < 500 group, 500 ~ 2.0 × 10e5group and > 2.0 × 10e5group was not statistically significant (P = 0.417).ConclusionHBV infection is an independent risk factor for early PTB, and the risk did not seem to be influenced by the levels of HBV DNA. Comprehensive programs focusing on pregnant women with HBV infection would reduce the incidence of adverse outcomes.
TRIM27 interacts with Iκbα to promote the growth of human renal cancer cells through regulating the NF-κB pathway
Authors: Xiao Chengwu , Zhang Wei , Hua Meimian , Chen Huan , Yang Bin , Wang Ye , Yang Qing 
Published: July 2021

Abstract
Background
The tripartite motif (TRIM) family proteins exhibit oncogenic roles in various cancers. The roles of TRIM27, a member of the TRIM super family, in renal cell carcinoma (RCC) remained unexplored. In the current study, we aimed to investigate the clinical impact and roles of TRIM27 in the development of RCC.

Methods
The mRNA levels of TRIM27 and Kaplan–Meier survival of RCC were analyzed from The Cancer Genome Atlas database. Real-time PCR and Western blotting were used to measure the mRNA and protein levels of TRIM27 both in vivo and in vitro. siRNA and TRIM27 were exogenously overexpressed in RCC cell lines to manipulate TRIM27 expression.

Results
We discovered that TRIM27 was elevated in RCC patients, and the expression of TRIM27 was closely correlated with poor prognosis. The loss of function and gain of function results illustrated that TRIM27 promotes cell proliferation and inhibits apoptosis in RCC cell lines. Furthermore, TRIM27 expression was positively associated with NF-κB expression in patients with RCC. Blocking the activity of NF-κB attenuated the TRIM27-mediated enhancement of proliferation and inhibition of apoptosis. TRIM27 directly interacted with Iκbα, an inhibitor of NF-κB, to promote its ubiquitination, and the inhibitory effects of TRIM27 on Iκbα led to NF-κB activation.

Conclusions
Our results suggest that TRIM27 exhibits an oncogenic role in RCC by regulating NF-κB signaling. TRIM27 serves as a specific prognostic indicator for RCC, and strategies targeting the suppression of TRIM27 function may shed light on future therapeutic approaches.
Scheimpflug analysis of corneal power changes after hyperopic small incision lenticule extraction
Authors: Fu Dan , Shang Jianmin , Zhang Xiaoyu , Niu Lingling , Han Tian , Zhou Xingtao 
Published: July 2021

Abstract
Purpose
To assess the ability of the Pentacam in predicting the corneal power after hyperopic small-incision lenticule extraction (SMILE).

Methods
Twenty-five eyes of 22 patients underwent hyperopic SMILE were prospectively followed. All patients finished at least 6 months visit. Cornea power was obtained by Pentacam HR, in the format of mean keratometry (Km), equivalent keratometry (EKR) and total cornea refractive power (TCRP). Calculation of TCRP were centered on either the corneal apex or the pupil center within a ring or zone, giving a total of four different subtypes naming AR、AZ、PR、PZ. Clinical history method (CHM) was regarded as a gold standard and was compared with other cornea power parameters.

Results
Center difference had no impact on the TCRP values (PR vs AR and PZ vs AZ, P > 0.05). Compared with CHM, no difference was found in Km, EKR 4.0 mm, EKR 4.5 mm, PR 3.0 mm, PR 4.0 mm, AR 3.0 mm and AR 4.0 mm. PR 4.0 mm showed the least difference with CHM (− 0.14 ± 1.03D, P > 0.05). The 95% limit of agreement (LOA) of the TCRPs and CHM was not close. The top two were PR 3.0 mm and PR 4.0 mm, LOA of which were − 2.20 to 1.84 D and − 2.18 to 1.68 D respectively. Central cornea thickness was correlated with error (TCRP – CHM) of PR 4.0 mm (r = 0.58, P = 0.003).

Conclusions
The Pentacam topographer is an alternative method of measuring corneal power in eyes after hyperopic SMILE. The optimal options seem to be the TCRP (PR 4.0 mm). The agreement needs more verifications.
Now and then: a ten-year comparison of young people in residential substance use disorder treatment receiving group dialectical behaviour therapy
Authors: Marceau Ely M. , Holmes Gabriella , Cutts Jane , Mullaney Lauren , Meuldijk Denise , Townsend Michelle L. , Grenyer Brin F. S. 
Published: July 2021

Abstract
Background
Reducing substance use in youth is a global health priority. We compared two cohorts from the same 12-week residential substance use disorder (SUD) facility over a 10 year period: Cohort A (2008–2009) and Cohort B (2018–2020). The essential components of the program remained the same with the primary treatment being dialectical behaviour therapy (DBT) plus residential milieu.

Methods
Young people in the current Cohort B (N = 100) versus historical Cohort A (N = 102) had a similar ratio of males (74 vs. 70%) but were slightly older (mean 20.6 vs. 19.5 years). Linear mixed models were used to model outcome measures (global psychiatric symptoms, substance use severity, and quality of life) longitudinally up to 12 months later.

Results
Baseline to end-of-treatment comparisons showed that the current Cohort B had overall higher levels of global psychiatric symptoms (d = 0.70), but both groups reduced psychiatric symptoms (Cohort A: d = 1.05; Cohort B: d = 0.61), and had comparable increases in confidence to resist substance use (d = 0.95). Longitudinal data from the current Cohort B showed significant decreases in substance use severity from baseline to 6-month follow-up (d = 1.83), which were sustained at 12-month follow-up (d = 0.94), and increases in quality of life from baseline to end-of-treatment (d = 0.83).

Conclusions
We demonstrate how DBT plus milieu residential care for young people continues to show positive effects in a 10-year comparison. However, youth seeking treatment today compared to 10 years ago evidenced higher acuity of psychiatric symptoms reinforcing the importance of continuous improvement of psychological treatments.

Trial registration
Australian New Zealand Clinical Trials Registry: trial IDACTRN12618000866202, retrospectively registered on 22/05/2018, .